Powder: -20°C for 3 years | In solvent: -80°C for 1 year
BMS-214662 is a potent and selective farnesyl transferase inhibitor that induces mitochondrial apoptosis in primitive CD34+ chronic myeloid leukemia (CML) stem cells/progenitors, and has the ability to selectively target CML stem cells/progenitors with antitumor activity.
パッケージサイズ | 在庫状況 | 単価(税別) |
---|---|---|
25 mg | 約6-8 週間 | ¥ 521,000 |
50 mg | 約6-8 週間 | ¥ 684,000 |
100 mg | 約6-8 週間 | ¥ 918,000 |
説明 | BMS-214662 is a potent and selective farnesyl transferase inhibitor that induces mitochondrial apoptosis in primitive CD34+ chronic myeloid leukemia (CML) stem cells/progenitors, and has the ability to selectively target CML stem cells/progenitors with antitumor activity. |
ターゲット&IC50 | KRas:2.3 μM , Ras-CVLL:1.3 μM , FTase:1.35 nM |
分子量 | 489.61 |
分子式 | C25H23N5O2S2 |
CAS No. | 195987-41-8 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 100 mg/mL (204.24 mM)
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
BMS-214662 195987-41-8 MAPK Raf BMS 214662 BMS214662 Inhibitor inhibitor inhibit